The heart of the matter

A new treatment for slowing CKD progression and reducing CV risk in patients with CKD associated with T2D

21 10 25 Aha Learning Studio Virtual Doctor Bag Insert Pdf Final

Recent advancements in clinical understanding of CKD associated with T2D and accompanying cardiovascular risk have informed new treatment options and strategies for disease management. This event will showcase a new prescription treatment for CKD associated with T2D, and present clinical safety and efficacy data for this treatment. How to identify appropriate adult patients with CKD associated with T2D and how to initiate treatment will also be discussed. After the presentation, there will be an opportunity for Q&A.

Michelle Weisfelner Bloom, MD
Co-Director, Stony Brook Cardio-Oncology Program
Director, Outpatient Services, Heart Failure and Cardiomyopathy Center
Cardiologist, Women’s Heart Center
Stony Brook, New York

Saturday, Nov. 13, 2021
11-11:45 a.m., EST

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

The American Heart Association (AHA) does not endorse any commercial products or programs. The links provided within this site are for convenience only, and are not an endorsement of either the linked-to entity, product or service.  AHA makes no warranties of any kind, express or implied, with regard to its third-party vendor websites.